Prostate Enucleation With Intravesical Botox Injections in Treating BPH and Bladder Overactivity

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the effect of intravesical Botox injections on lower urinary tract symptoms (LUTS) when administered during ThuLEP surgery in patients with bladder outlet obstruction (BOO) and overactive bladder symptoms (OAB).

Detailed Description
-----------------
Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in men. Almost 90% of men in their 70s report lower urinary tract symptoms related to BPH. These symptoms carry a significant negative impact on the patients' quality of life. Despite the wide availability of surgical offerings to relieve bladder outlet obstruction such as transurethral resection of the prostate (TURP), Thulium Laser Enucleation of the Prostate (ThuLEP), and prostatectomy, many patients still suffer from persistent LUTS after undergoing these. A study describing postoperative outcomes following HoLEP revealed that patients with severe lower urinary tract symptoms, storage-positive sub-score, and high maximum urinary flow rate before the surgery were affected by a rebound of mainly storage symptoms 6-8 weeks after HoLEP and prolonged recovery from LUTS with 7.4% of them presenting for persistent urge complaints. Optimizing the management approach for these patients has been limited by lack of high level evidence-based recommendations and expert consensus. Intravesical botox injections are well-established therapeutic options for several urinary disorders. The current practice offers intravesical botox injections to patients who suffer from persistent urinary symptoms few months after their BPH procedure. This study aims to evaluate if giving botox injections at the time of the HoLEP surgery would yield a better outcome than performing the two procedures separately at different times (few months apart). The concomitant use of botox injection during bladder de-obstructing procedures has been previously studied in TURP and have showed a significant reduction of incontinence episodes and OAB symptoms in the group that were treated with botox injections after 36 weeks post TURP. This data may suggest promising potential of this intervention in managing persistent OAB symptoms in patients with BOO. However, the efficacy of combining HoLEP and bladder Botox injections has not been systematically studied and evaluated. The aim of this study is to evaluate the effect of intravesical Botox injections on lower urinary tract symptoms (LUTS) when administered during ThuLEP surgery in patients with bladder outlet obstruction (BOO) and overactive bladder symptoms (OAB). The investigators are interested in comparing the postoperative outcome in terms of recovery and symptom relief in patients who performed HoLEP surgery with bladder Botox injections versus those who performed HoLEP surgery only at 2 weeks,1 month, 3 months, and 6 months postoperatively. The investigators hypothesize that administering bladder botox injections during ThuLEP surgery is a combination treatment that will result in faster and more potent symptom relief compared to patients who received only a ThuLEP surgery for their obstructive and irritative symptoms

Official Title
-----------------
Prostate Enucleation With Intravesical Botox Injections in Treating Benign Prostatic Hyperplasia and Bladder Overactivity : A Randomized Controlled Trial

Conditions
-----------------
BPH, Intravesical Botox, ThuLEP, Overactive Bladder, Bladder Outlet Obstruction

Intervention / Treatment
-----------------
* Procedure: Thulium Laser Enucleation of the Prostate (ThuLEP)
* Drug: Intravesical Botox injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males age > 40 Patients diagnosed with Benign Prostatic Hyperplasia (BPH) and referred for ThuLEP surgery Lower urinary tract symptoms (LUTS) of Overactive Bladder Syndrome (OABS) frequency - urgency - urge incontinence episodes - dysuria - nocturia and eligible for bladder botox injections International Prostate Symptom Score (IPSS) ≥ 17 Overactive Bladder Symptom Score (OABSS) ≥ 7 Participants have failed, are intolerant, or bad candidates for anticholinergic medication treatment for OAB Exclusion Criteria: History of bladder/prostate cancer History of pelvic radiotherapy History of neurological diseases Presence of active Urinary Tract Infection (UTI) Previous Bladder Outlet Procedure (Transurethral resection of prostate (TURP) Transurethral Incision of Prostate (TUIP) - UroLift, etc..) History of adverse reaction to Botox injections Post-void residual (PVR) greater than 300 ml History of clean intermittent catheterization Patients unable to stop anticoagulation of antiplatelet inhibitors 3 days prior to procedure

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: This study will be a randomized clinical trial. The study team is interested in approaching and recruiting patients who were referred for ThuLEP surgery for their urinary symptoms and also eligible for intravesical Botox injections. This cohort of patients will be recruited and randomized into two groups: a control group that would undergo ThuLEP procedure only, and an experimental group that will undergo ThuLEP procedure combined with an intravesical Botox injection. This study will utilize a 1:1 randomization scheme to assign participants to either the control group or the experimental group. Participants will not be blinded to the procedure they are receiving. No one on the study team including those involved in data analysis will be blinded to the study arm assignment. The investigators plan to recruit a maximum of 50 participants in each arm. The study's intervention is whether Botox injections are added during the surgery or not.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients receiving ThuLEP surgery only<br>50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for ThuLEP to treat their urinary symptoms. No Botox injections will be given. | Procedure: Thulium Laser Enucleation of the Prostate (ThuLEP)<br>* Thulium Laser Enucleation of the Prostate<br>|
| Experimental: Patients receiving ThuLEP surgery + Intravesical Botox Injections<br>50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for ThuLEP to treat their urinary symptoms. Botox injections will be given during the surgery. | Procedure: Thulium Laser Enucleation of the Prostate (ThuLEP)<br>* Thulium Laser Enucleation of the Prostate<br>Drug: Intravesical Botox injection<br>* Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in International Prostate Symptom Score (IPSS) | Comparing the change in IPSS score between the two arms across time | IPSS scores will be recorded before the surgery and at 4 checkpoints after the surgery during every clinical visit: 2 weeks -1 month - 3 months - 6 months postoperatively | 
| Change in Overactive Bladder Symptoms Score (OABSS) | Comparing the change in OABSS score between the two arms across time | OABSS scores will be recorded before the surgery and at 4 checkpoints after the surgery during every clinical visit: 2 weeks -1 month - 3 months - 6 months postoperatively | 
| Change in Maximum Urinary Flow rate | Comparing the change in maximum urinary flow rate(mL/sec) between the two arms across time | Uroflowmetry will be performed before the surgery and at 4 checkpoints after the surgery during every clinical visit: 2 weeks -1 month - 3 months - 6 months postoperatively | 
| Change in Post-Void Residual (PVR) Volume | Comparing the change in postvoid residual volume (mL) between the two arms across time | Postvoid residual volume (mL) will be performed before the surgery and at 4 checkpoints after the surgery during every clinical visit: 2 weeks -1 month - 3 months - 6 months postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events | Any adverse events in the context of readmissions, emergency department visits, and clinical visits will be recorded | Adverse events will be monitored throughout the entire study duration (6 months after the surgery) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intravesical Botox, ThuLEP, BPH, Overactive Bladder, Bladder Outlet Obstruction